Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
450 participants
INTERVENTIONAL
2011-09-30
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber
NCT02166268
To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis
NCT00679250
A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
NCT04881461
Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848
NCT01185080
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
NCT00773240
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Avanz Phleum pratense 15,000 SQ+
Avanz Phleum pratense
Suspension for Injection, Every 6 weeks for one year
Avanz Phleum pratense 4,000 SQ+
Avanz Phleum pratense
Suspension for Injection, Every 6 weeks for one year
Injection with no active grass component
Placebo
Suspension for Injection, Every 6 weeks for one year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avanz Phleum pratense
Suspension for Injection, Every 6 weeks for one year
Placebo
Suspension for Injection, Every 6 weeks for one year
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive skin prick test to grass
* Positive Immunoglobulin E test to grass
Exclusion Criteria
* Severe Asthma (defined as a Forced expiratory volume in 1 second (FEV1) below 70 % after adequate treatment)
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALK-Abelló A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jörg Kleine-Tebbe, PD Dr.
Role: PRINCIPAL_INVESTIGATOR
Clinical Research Center for Dermatology, Allergy and Asthma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UntersuchungsZentrum für Dermatologie, Allergologie und Asthma
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AV-G-02
Identifier Type: -
Identifier Source: secondary_id
AV-G-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.